Loading company
Acurx Pharmaceuticals, Inc.
ACXP · Nasdaq · ·
Next earnings: November 11, 2026
$1.31-2.6%Sep 29 close
- 1M
- -9.4%
- 6M
- -62.7%
- 1Y
- -69.6%
- 5Y
- -98.6%
ACXP · Nasdaq · ·
Next earnings: November 11, 2026
$1.31-2.6%Sep 29 close
Acurx Pharmaceuticals, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$2.3M | -$2.2M | -0.35% |
| Profit per share | -$0.53 | -$1.89 | +71.96% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Acurx Pharmaceuticals, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Ibezapolstat is the Company’s lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS ® ) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Acurx Pharmaceuticals, Inc.’s Item 2.02 8-K filed May 13, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.